Guggenheim raised the firm’s price target on Eli Lilly (LLY) to $948 from $875 and keeps a Buy rating on the shares. Following checks with IR and the firm’s U.S. Rx and outside of the U.S. business trend review, it now forecasts Q3 Mounjaro sales of $5.486B, which includes U.S. sales of $3.501B, and sees room for upside depending on international dynamics, the analyst tells investors in a preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- 3 “Strong Buy” Growth Stocks to Buy Now, According to Analysts – 10/7/2025
- Former FDA vaccine regulation head Peter Marks to join Eli Lilly, STAT reports
- Novo Nordisk (NVO) Cuts Jobs at Key US Site amid Global Restructuring Drive
- Eli Lilly reports final results from LUCENT-3 study of Omvoh
- UNH vs. LLY vs. HIMS: Which Healthcare Stock Is the Best Pick, According to Analysts?